TickerFacts.

Vir Biotechnology, Inc. (VIR): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$391.78M
Year ended 2025-12-31
-$202.51M
Trailing 12 months to 2026-06-30
$1.66B2017-12-31: -$66.38M2018-12-31: -$94.10M2019-12-31: -$129.63M2020-12-31: -$190.94M2021-12-31: -$47.59M2022-12-31: $1.66B2023-12-31: -$778.78M2024-12-31: -$446.35M2025-12-31: -$391.78M-$391.78M
2017-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$391.78Mn/m2026-02-23, From 2025-01-01
2024-12-31-$446.35Mn/m2026-02-23, From 2024-01-01
2023-12-31-$778.78Mn/m2026-02-23, From 2023-01-01
2022-12-31$1.66Bn/m2025-02-27, From 2022-01-01
2021-12-31-$47.59Mn/m2024-02-26, From 2021-01-01
2020-12-31-$190.94Mn/m2023-02-28, From 2020-01-01
2019-12-31-$129.63Mn/m2022-02-28, From 2019-01-01
2018-12-31-$94.10Mn/m2021-02-25, From 2018-01-01
2017-12-31-$66.38Mn/a2020-03-26, From 2017-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Vir Biotechnology, Inc. (VIR)2025-12-31-$391.78Mn/m
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$29.61Mn/m
Compugen Ltd (CGEN)2025-12-31$31.63M-36.2%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31-$371.81Mn/m
Autolus Therapeutics plc (AUTL)2025-12-31-$283.57Mn/m
Champions Oncology, Inc. (CSBR)2026-04-30-$4.47Mn/m
MeiraGTx Holdings plc (MGTX)2025-12-31-$46.36Mn/m
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31-$109.08Mn/m
Invivyd, Inc. (IVVD)2025-12-31-$58.13Mn/m

Compare VIR, BDTX, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗